Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
Background: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated.Methods: A pre-treatme...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00789/full |
| _version_ | 1831615087693004800 |
|---|---|
| author | Ashley M. Hopkins Andrew Rowland Ross A. McKinnon Michael J. Sorich |
| author_facet | Ashley M. Hopkins Andrew Rowland Ross A. McKinnon Michael J. Sorich |
| author_sort | Ashley M. Hopkins |
| collection | DOAJ |
| description | Background: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated.Methods: A pre-treatment prognostic model for progression-free survival (PFS) and overall survival (OS) was developed for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel using clinicopathological data from the randomized clinical trial CLEOPATRA (n = 408). Cox proportional hazard analysis with a backwards deletion process was used.Results: Metastatic sites count (<3 vs. ≥ 3) and lactate dehydrogenase (LDH) (≤ ULN vs. >ULN) were identified as common pre-treatment risk predictors for PFS and OS (P < 0.05). Based on these two factors, patients can be characterized as one of three prognostic groups (good = 0 factors; intermediate = 1 factor; poor = 2 factors). The prognostic groups were associated with significantly different PFS (P < 0.001), with 3-year PFS probabilities of 44% (36–55), 28% (22–36), and 17% (11–29) for the good, intermediate and poor prognostic groups, respectively. Similarly, there was significant differences in OS (P < 0.001), with 4-year OS probabilities of 75% (95% CI: 67–84), 60% (53–68) and 31% (21–45) for the good, intermediate and poor prognostic groups, respectively.Conclusions: Pre-treatment prognostic groups identified for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel had significantly different long-term disease control and survival outcomes. |
| first_indexed | 2024-12-18T19:41:14Z |
| format | Article |
| id | doaj.art-213f1c21288b4360a5b8d2e793f072c7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-18T19:41:14Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-213f1c21288b4360a5b8d2e793f072c72022-12-21T20:55:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-08-01910.3389/fonc.2019.00789469855Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and DocetaxelAshley M. HopkinsAndrew RowlandRoss A. McKinnonMichael J. SorichBackground: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated.Methods: A pre-treatment prognostic model for progression-free survival (PFS) and overall survival (OS) was developed for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel using clinicopathological data from the randomized clinical trial CLEOPATRA (n = 408). Cox proportional hazard analysis with a backwards deletion process was used.Results: Metastatic sites count (<3 vs. ≥ 3) and lactate dehydrogenase (LDH) (≤ ULN vs. >ULN) were identified as common pre-treatment risk predictors for PFS and OS (P < 0.05). Based on these two factors, patients can be characterized as one of three prognostic groups (good = 0 factors; intermediate = 1 factor; poor = 2 factors). The prognostic groups were associated with significantly different PFS (P < 0.001), with 3-year PFS probabilities of 44% (36–55), 28% (22–36), and 17% (11–29) for the good, intermediate and poor prognostic groups, respectively. Similarly, there was significant differences in OS (P < 0.001), with 4-year OS probabilities of 75% (95% CI: 67–84), 60% (53–68) and 31% (21–45) for the good, intermediate and poor prognostic groups, respectively.Conclusions: Pre-treatment prognostic groups identified for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel had significantly different long-term disease control and survival outcomes.https://www.frontiersin.org/article/10.3389/fonc.2019.00789/fullanti-HER2 therapiesadvanced breast cancerprognostic modelpertuzumabtrastuzumabsurvival |
| spellingShingle | Ashley M. Hopkins Andrew Rowland Ross A. McKinnon Michael J. Sorich Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel Frontiers in Oncology anti-HER2 therapies advanced breast cancer prognostic model pertuzumab trastuzumab survival |
| title | Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel |
| title_full | Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel |
| title_fullStr | Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel |
| title_full_unstemmed | Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel |
| title_short | Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel |
| title_sort | predictors of long term disease control and survival for her2 positive advanced breast cancer patients treated with pertuzumab trastuzumab and docetaxel |
| topic | anti-HER2 therapies advanced breast cancer prognostic model pertuzumab trastuzumab survival |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00789/full |
| work_keys_str_mv | AT ashleymhopkins predictorsoflongtermdiseasecontrolandsurvivalforher2positiveadvancedbreastcancerpatientstreatedwithpertuzumabtrastuzumabanddocetaxel AT andrewrowland predictorsoflongtermdiseasecontrolandsurvivalforher2positiveadvancedbreastcancerpatientstreatedwithpertuzumabtrastuzumabanddocetaxel AT rossamckinnon predictorsoflongtermdiseasecontrolandsurvivalforher2positiveadvancedbreastcancerpatientstreatedwithpertuzumabtrastuzumabanddocetaxel AT michaeljsorich predictorsoflongtermdiseasecontrolandsurvivalforher2positiveadvancedbreastcancerpatientstreatedwithpertuzumabtrastuzumabanddocetaxel |